Quote:
Originally Posted by Curt D 
I'm glad I sold on Friday!
|
Aaron Whiteman, CEO for GENova says, "Following a rigorous evaluation phase, we have selected three potential blockbuster drug target patents for acquisition, and we look forward to integrating them into our IP portfolio." The acquisition targets still subject to due diligence and contract would include both preclinical and clinical drugs that show promising potential in the major markets of anti-cancer and anti-infective drugs.
GENova will announce details of these new biological products in the coming weeks.
And this why I'm holding and buying more , "in the coming weeks"
